Investigating Whether Acute Elevation of Fatty Acid Levels Alters Cerebral Glucose Transport and Metabolism
Who is this study for? Individuals with obesity
What treatments are being studied? Intralipid
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
The goal of this study is to understand the role of brain glucose transport in individuals with obesity and the association with cerebral hypometabolism and these individuals' response to plasma glucose elevations. The main premise is that obesity leads to reduced brain glucose transport and that we can measure this reduction with magnetic resonance spectroscopy (MRS). The secondary premises are that this reduction is driven by elevated non esterified fatty acids which act to turn on specific signaling pathways that regulate brain GLUT1 levels.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 45
Healthy Volunteers: t
View:
• Age 18-45 years
• HbA1C \<6.5%
• Normal weight individuals: BMI 17-25 kg/m\^2
• Obese individuals: BMI \>30 kg/m\^2
Locations
United States
North Carolina
Biomedical Research Imaging Center Marsico Hall (UNC)
RECRUITING
Chapel Hill
Clinical and Translational Research Center (CTRC) Burnett-Womack Building (UNC)
RECRUITING
Chapel Hill
Contact Information
Primary
Joseph Palmiotto
joseph_palmiotto@med.unc.edu
919-966-9184
Time Frame
Start Date: 2020-12-08
Estimated Completion Date: 2026-06-01
Participants
Target number of participants: 40
Treatments
Experimental: Non-diabetic, normal weight individuals receiving Intralipid
Non-diabetic, normal weight individuals receiving Intralipid. Participants will receive an infusion of Intralipid 20% for 12 hours through an IV (prior to and during scan #2)
Placebo_comparator: Non-diabetic, normal weight individuals receiving saline
Non-diabetic, normal weight individuals receiving saline. Participants will receive an infusion of normal saline (1:1 randomization) at 30 ml/hr for 12 hours through an IV (prior to and during scan #2
Authors
Related Therapeutic Areas
Sponsors
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Leads: University of North Carolina, Chapel Hill